Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

Joseph Saad, Samuli Eldfors, Vilma Ikonen, Bjørn Tore Gjertsen, Mika Kontro, Kimmo Porkka, Caroline A. Heckman

Blood (2022) 140 (Supplement 1): 1033–1035.

https://doi.org/10.1182/blood-2022-163242

Published: 2022

Journal Articles

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Blood (2022) 140 (Supplement 1): 9125–9127.

https://doi.org/10.1182/blood-2022-157753

Published: 2022

Journal Articles

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Jesse M. Tettero, Lok Lam Ngai, Costa Bachas, Dimitri A. Breems, Thomas Fischer, Bjørn Tore Gjertsen, Patrycja Gradowska, Laimonas Griskevicius, Jeroen J.W.M. Janssen, Gunnar Juliusson, Johan A. Maertens, Markus G Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Peter JM Valk, Bob Lowenberg, Gert J. Ossenkoppele, Jacqueline Cloos

Blood (2022) 140 (Supplement 1): 2027–2029.

https://doi.org/10.1182/blood-2022-157009

Published: 2022

Journal Articles

Conversion from MRD Positive to Negative Status in AML Patients in CR1 after Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Arjan van de Loosdrecht, MD PhD, Janine van Elssen, MDPhD, Bjørn Tore Gjertsen, Eva Maria Wagner, MD, Tobias Holderried, MD, Uwe Platzbecker, Jacqueline J Cloos, Jeroen Rovers, MD PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139266

Published: 2020

Journal Articles

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Jinhong Fan, Hongbin Wang, Suzana Couto, Tsun-Wen Sheena Yao, Geoffrey L. Uy, MD, Amer M. Zeidan, MBBS, MHS, Mark D. Minden, Pau Montesinos, Daniel J. DeAngelo, Jessica K. Altman, Jamie Koprivnikar, MD, Paresh Vyas, MD PhD, Yngvar Fløisand, María Belén Vidriales, Bjørn Tore Gjertsen, Tonia J. Buchholz, Michael Pourdehnad, Daniel W. Pierce

Blood (2019) 134 (Supplement_1): 2547.

https://doi.org/10.1182/blood-2019-124291

Published: 2019

Journal Articles

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

Blood (2019) 134 (Supplement_1): 232.

https://doi.org/10.1182/blood-2019-123966

Published: 2019

Journal Articles

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Disha Malani, MRes, Ashwini Kumar, MRes, Bhagwan Yadav, PhD, Mika Kontro, MD, Swapnil Potdar, MSc, Samuli Eldfors, MSc, Jani Saarela, Bjørn Tore Gjertsen, Riikka Karjalainen, Tero Aittokallio, Astrid Murumagi, Maija Wolf, PhD, Simon Anders, PhD, Krister Wennerberg, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD

Blood (2017) 130 (Supplement 1): 854.

https://doi.org/10.1182/blood.V130.Suppl_1.854.854

Published: 2017

Journal Articles

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

Sonja Loges, MD PhD, Bjørn Tore Gjertsen, Michael Heuser, MD, Joerg Chromik, Isabel Ben-Batalla, Nuray Akyüz, David Micklem, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 1375.

https://doi.org/10.1182/blood.V130.Suppl_1.1375.1375

Published: 2017

Journal Articles

Development of Novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia

Misbah Sabir, MSc, Monica Hellesoy, PhD, Jarno Kivioja, MSc, Caroline Engen, MD, Claire Amiable, Mihaela Popa, Remi Guillon, Øystein Bruserud, MD PhD, Caroline A Heckman, PhD, Emmet McCormack, BSc, PhD, Dominique Surleraux, Bjørn Tore Gjertsen

Blood (2017) 130 (Supplement 1): 3349.

https://doi.org/10.1182/blood.V130.Suppl_1.3349.3349

Published: 2017

Journal Articles

Dasatinib Treatment Induces Fast and Deep Responses In Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients In Chronic Phase: Clinical Results From a Randomized Phase 2 Study (NordCML006)

Henrik Hjorth-Hansen, MD, PhD, Johan Richter, MD, PhD, Leif Stenke, MD, PhD, Hans Ehrencrona, MD, PhD, Bjørn Tore Gjertsen, MD, PhD, Tobias Gedde-Dahl, III, MD, PhD, Perttu Koskenvesa, MD, Claes Malm, MD, Waleed Majeed, MD, Lotta Ohm, MD PhD, Martin Hoglund, MD PhD, Ulla Olsson-Strömberg, MD, PhD, Stina Söderlund, MD, Merja Suominen, MD, Kari Remes, MD PhD, Berit Markevärn, MD, Bengt Simonsson, MD PhD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD

Blood (2013) 122 (21): 4032.

https://doi.org/10.1182/blood.V122.21.4032.4032

Published: 2013

Journal Articles

Elacytarabine Is More Effective Preclinically Than Cytarabine In Combination With Daunorubicin In Primary Patient Xenografts Of AML

Tereza Osdal, MSc, Mihaela Lucia Popa, VMD, Lene Mari Vikebø, Andre Sulen, MSc, Siv Lise Bendringaas, Marit Liland Sandvold, PhD, Birgitte Booij, PhD, Øystein Bruserud, MD, PhD, Bjørn Tore Gjertsen, MD, PhD, Emmet McCormack, PhD

Blood (2013) 122 (21): 3958.

https://doi.org/10.1182/blood.V122.21.3958.3958

Published: 2013

Journal Articles

Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia

Emmet McCormack, Maja Mujić, Tereza Osdal, Øystein Bruserud, Bjørn Tore Gjertsen

Blood (2013) 121 (7): e34–e42.

https://doi.org/10.1182/blood-2012-05-429555

Published: 2013

Includes: Supplemental data

Journal Articles

Evaluation of Combinational Therapy of MDM2-Antagonist Nutlin-3 and HDAC-Inhibitor Valproic Acid in Acute Myeloid Leukemia in Vitro and in Vivo

Emmet McCormack, Ingvild Haaland, Gurid Venås, Rakel Brendsdal Forthun, Øystein Bruserud, Bjørn Tore Gjertsen

Blood (2008) 112 (11): 2981.

https://doi.org/10.1182/blood.V112.11.2981.2981

Published: 2008

Journal Articles

Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death

Gro Gausdal, Bjørn Tore Gjertsen, Emmet McCormack, Petra Van Damme, Randi Hovland, Camilla Krakstad, Øystein Bruserud, Kris Gevaert, Joël Vandekerckhove, Stein Ove Døskeland

Blood (2008) 111 (5): 2866–2877.

https://doi.org/10.1182/blood-2007-07-103242

Published: 2008

Includes: Supplemental data

Journal Articles

Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients

Sigbjørn Berentsen, Elling Ulvestad, Bjørn Tore Gjertsen, Henrik Hjorth-Hansen, Ruth Langholm, Håvar Knutsen, Waleed Ghanima, Fuad Victor Shammas, Geir E. Tjønnfjord

Blood (2004) 103 (8): 2925–2928.

https://doi.org/10.1182/blood-2003-10-3597

Published: 2004

NARROW

Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Conversion from MRD Positive to Negative Status in AML Patients in CR1 after Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

Development of Novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia

Dasatinib Treatment Induces Fast and Deep Responses In Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients In Chronic Phase: Clinical Results From a Randomized Phase 2 Study (NordCML006)

Elacytarabine Is More Effective Preclinically Than Cytarabine In Combination With Daunorubicin In Primary Patient Xenografts Of AML

Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia

Evaluation of Combinational Therapy of MDM2-Antagonist Nutlin-3 and HDAC-Inhibitor Valproic Acid in Acute Myeloid Leukemia in Vitro and in Vivo

Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death

Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only